4D Molecular Therapeutics, Inc.FDMTNASDAQ
Loading
FDMT Revenue Growth (YoY Quarterly)•+8508900.00%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+8508900.00%
+8506000.0pp
+0.00%
+1571700.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+7.39%
+6.4pp
+7.39%
+6.4pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | -50.00% | +200.00% | +2900.00% | +8508900.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | -1571700.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +37.86% | +13.14% | +1.17% | +1.03% | +7.39% |
| Weighted Average Shares Diluted Growth | +37.86% | +13.14% | +1.17% | +1.03% | +7.39% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +64.87% | -18.12% | -23.62% | -29.81% | +1.13% |
| Book Value per Share Growth | +20.32% | -30.87% | -29.29% | -33.95% | -7.78% |
| Debt Growth | +67.72% | +68.32% | +68.99% | -10.35% | -12.98% |
| R&D Expense Growth | +65.53% | +46.03% | +50.51% | +28.46% | +33.71% |
| SG&A Expenses Growth | +37.93% | +25.67% | +8.67% | -6.43% | -12.72% |
1 / 4